Browsing Tag
Mayo Clinic
15 posts
Optiscan Imaging (ASX: OIL) files FDA dossier for InSpecta veterinary device, targeting an $11.9bn market
Optiscan Imaging (ASX: OIL) has filed its FDA dossier for InSpecta, targeting the US$11.9bn U.S. veterinary market. Read what this milestone means for investors.
4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83m to accelerate European commercial launch
4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83M to fund EU expansion. Read what this means for investors and the respiratory imaging sector.
Could GraftAssureDx reshape access to transplant rejection monitoring? (Nasdaq: IMDX)
Could GraftAssureDx decentralize transplant rejection monitoring? Learn what Insight Molecular Diagnostics Inc.’s FDA push means for transplant diagnostics.
How Lumee Oxygen could influence intraoperative decision-making in limb ischemia
Profusa, Inc. raises guidance as Lumee Oxygen gains traction in Europe. Discover how real-time oxygen data could reshape limb ischemia surgery.
EMVision (ASX:EMV) ramps up stroke scanner trial with full site activation, algorithm updates, and U.S. expansion
EMVision’s emu scanner trial is gaining momentum across top U.S. and Australian hospitals. Find out how AI upgrades and regional pilots may shape FDA clearance.
From military tech to ICU wards: Detect-ION’s bold new vision for breath-based infection testing
Detect-ION and Mayo Clinic are co-developing a breath-based pneumonia test using VOC biomarkers. Find out how this could reshape hospital diagnostics.
Can AI predict heart failure years earlier? Inside Anumana’s breakthrough AHA 2025 results
Anumana’s FDA-cleared ECG-AI platform enhances heart failure prediction and expands into perioperative care with Boston Scientific’s backing. Learn more.
Why Japan’s review of Ferring’s bladder cancer gene therapy candidate could reshape urology
Discover how Ferring’s gene therapy nadofaragene firadenovec could transform NMIBC treatment in Japan after PMDA NDA acceptance.
Can Google Cloud turn its $1.2bn ServiceNow win into broader enterprise momentum?
Can Google Cloud build on its $1.2B ServiceNow deal to win more Fortune 500 clients? Explore the momentum and what it signals for enterprise cloud adoption.
ATOMIC trial breakthrough: Atezolizumab + FOLFOX cuts colon cancer recurrence risk by 50%
Atezolizumab plus FOLFOX slashes recurrence risk in stage III dMMR colon cancer, says ATOMIC trial at ASCO 2025. Is this the new standard of care?